{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T02:03:50Z","timestamp":1794535430606,"version":"4.9.1"},"reference-count":73,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["KK.01.1.1.04.0115."],"award-info":[{"award-number":["KK.01.1.1.04.0115."]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background\/Objectives: Cardiometabolic risk remains a major challenge in patients with type 2 diabetes mellitus (DMT2). This study aimed to evaluate cardiovascular (CV) risk stratification using advanced glycation end-products (AGEs) measured via skin autofluorescence (SAF) and to assess the achievement of evidence-based ABC targets (HbA1c, blood pressure, low-density lipoprotein (LDL) cholesterol) in adults with DMT2 in Dalmatia. Methods: In this single-center cross-sectional study, 251 adults with DMT2 were stratified by CV risk based on SAF measured AGE levels. Clinical, biochemical, and anthropometric data were collected, including ABC goal attainment and medication use. Statistical analyses compared groups and explored predictors of ABC target achievement using regression models adjusted for clinical factors. Results: Only 17.5% of participants achieved all three ABC goals, indicating suboptimal cardiometabolic control. Those with elevated CV risk had higher hip circumference and lower diastolic blood pressure. Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors was positively associated with ABC goal achievement in patients with prior CV or cerebrovascular events, while higher body mass index was negatively associated. SAF measured AGE levels correlated with cardiometabolic risk but showed no significant differences across LDL cholesterol or other traditional markers. Conclusions: SAF AGE measurement shows potential for CV risk stratification in DMT2 beyond traditional factors. The low rate of ABC goal attainment highlights the need for intensified individualized management incorporating novel biomarkers and therapeutics like SGLT2 inhibitors. Further prospective studies are needed to validate these findings and improve prevention of cardiovascular complications in DMT2.<\/jats:p>","DOI":"10.3390\/biomedicines13102418","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:18:33Z","timestamp":1759421913000},"page":"2418","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Public Health Screening for Cardiometabolic Risk: Lessons from Advanced Glycation End-Products and ABC Target Achievement in Dalmatian Adults with Type 2 Diabetes"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-7597","authenticated-orcid":false,"given":"Josipa","family":"Radi\u0107","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, Dialysis and Arterial Hypertension, University Hospital of Split, 21000 Split, Croatia"},{"name":"Internal Medicine Department, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijana","family":"Vu\u010dkovi\u0107","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Nephrology, Dialysis and Arterial Hypertension, University Hospital of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2188-0006","authenticated-orcid":false,"given":"Hana","family":"\u0110oga\u0161","sequence":"additional","affiliation":[{"name":"Department of Neurology, University Hospital of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3374-2906","authenticated-orcid":false,"given":"Anders","family":"\u00d8deverp","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, School of Medicine, University of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2781-6280","authenticated-orcid":false,"given":"Marina","family":"Grubi\u0107","sequence":"additional","affiliation":[{"name":"Institute for Emergency Medicine of Split-Dalmatia County, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0350-6800","authenticated-orcid":false,"given":"Mislav","family":"Radi\u0107","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, School of Medicine, University of Split, 21000 Split, Croatia"},{"name":"Department of Internal Medicine, Division of Rheumatology, Allergology and Clinical Immunology, University Hospital of Split, 21000 Split, Croatia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(20)32374-6","article-title":"The Lancet Commission on Diabetes: Using Data to Transform Diabetes Care and Patient Lives","volume":"396","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e2004","DOI":"10.1002\/hsr2.2004","article-title":"Diabetes Mellitus, the Fastest Growing Global Public Health Concern: Early Detection Should Be Focused","volume":"7","author":"Hossain","year":"2024","journal-title":"Health Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global Prevalence of Diabetes: Estimates for the Year 2000 and Projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_4","unstructured":"Dianna, J. (2025). Magliano. IDF Atlas 11th Edition 2025, International Diabetes Federation. [11th ed.]."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global Aetiology and Epidemiology of Type 2 Diabetes Mellitus and Its Complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Al Epidemiology of Type 2 Diabetes\u2014Global Burden of Disease and Forecasted Trends","volume":"10","author":"Khan","year":"2020","journal-title":"J. Epidemiol. Glob. Health"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"The Lancet (2023). Diabetes: A Defining Disease of the 21st Century. Lancet, 401, 2087.","DOI":"10.1016\/S0140-6736(23)01296-5"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Huang, X., Wu, Y., Ni, Y., Xu, H., and He, Y. (2025). Global, Regional, and National Burden of Type 2 Diabetes Mellitus Caused by High BMI from 1990 to 2021, and Forecasts to 2045: Analysis from the Global Burden of Disease Study 2021. Front. Public Health, 13.","DOI":"10.3389\/fpubh.2025.1515797"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"American Diabetes Association (2014). Standards of Medical Care in Diabetes-2014. Diabetes Care, 37, S14\u2013S80.","DOI":"10.2337\/dc14-S014"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2024). 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes\u20142024. Diabetes Care, 47, S52\u2013S76.","DOI":"10.2337\/dc24-S004"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.2337\/dci23-0036","article-title":"Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus","volume":"46","author":"Sacks","year":"2023","journal-title":"Diabetes Care"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group (1998). Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ, 317, 713\u2013720.","DOI":"10.1136\/bmj.317.7160.713"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"UK Prospective Diabetes Study Group (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 317, 70\u2013713.","DOI":"10.1136\/bmj.317.7160.703"},{"key":"ref_14","unstructured":"Anwer, Z., Sharma, P.K., Garg, V.K., Kumar, N., and Kumari, A. (2011). Hypertension Management in Diabetic Patients. Eur. Rev. Med. Pharmacol. Sci., 15."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33)","volume":"352","author":"Turner","year":"1998","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Heart Protection Study Collaborative Group (2003). MRC\/BHF Heart Protection Study of Cholesterol-Lowering with Simvastatin in 5963 People with Diabetes: A Randomised Placebo-Controlled Trial. Lancet, 361, 2005\u20132016.","DOI":"10.1016\/S0140-6736(03)13636-7"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","article-title":"Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease","volume":"78","author":"Jia","year":"2021","journal-title":"Hypertension"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41440-018-0034-4","article-title":"Hypertension with Diabetes Mellitus: Physiology and Pathology Review-Article","volume":"41","author":"Ohishi","year":"2018","journal-title":"Hypertens. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","article-title":"Diabetes and Hypertension: The Bad Companions","volume":"380","author":"Ferrannini","year":"2012","journal-title":"Lancet"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/jama.2014.18574","article-title":"Blood Pressure Lowering in Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"313","author":"Emdin","year":"2015","journal-title":"JAMA"},{"key":"ref_21","first-page":"575","article-title":"Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms","volume":"34","author":"Petrie","year":"2018","journal-title":"Can. J. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.atherosclerosis.2015.01.039","article-title":"New Insights into the Pathophysiology of Dyslipidemia in Type 2 Diabetes","volume":"239","author":"Taskinen","year":"2015","journal-title":"Atherosclerosis"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.5551\/jat.RV17023","article-title":"Pathophysiology of Diabetic Dyslipidemia","volume":"25","author":"Hirano","year":"2018","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-Rich Lipoproteins and Their Remnants: Metabolic Insights, Role in Atherosclerotic Cardiovascular Disease, and Emerging Therapeutic Strategies-a Consensus Statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Eilat-Tsanani, S., Margalit, A., and Golan, L.N. (2021). Occurrence of Comorbidities in Newly Diagnosed Type 2 Diabetes Patients and Their Impact after 11 Years\u2019 Follow-Up. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-90379-0"},{"key":"ref_26","first-page":"e60268","article-title":"Interplay Between the American Diabetes Association\u2019s ABC Targets for Diabetes, Insulin Resistance Indices, and Dyslipidemia in Indian Type 2 Diabetes Patients","volume":"16","author":"Tripathi","year":"2024","journal-title":"Cureus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.dsx.2020.05.015","article-title":"Inadequate Achievement of ABC Goals (HbA1c, Blood Pressure, LDL-C) among Patients with Type 2 Diabetes in an Iranian Population, 2012\u20132017","volume":"14","author":"Larry","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mengstie, M.A., Chekol Abebe, E., Behaile Teklemariam, A., Tilahun Mulu, A., Agidew, M.M., Teshome Azezew, M., Zewde, E.A., and Agegnehu Teshome, A. (2022). Endogenous Advanced Glycation End Products in the Pathogenesis of Chronic Diabetic Complications. Front. Mol. Biosci., 9.","DOI":"10.3389\/fmolb.2022.1002710"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1089\/ars.2009.2484","article-title":"Hyperglycemia and Glycation in Diabetic Complications","volume":"11","author":"Salvayre","year":"2009","journal-title":"Antioxid. Redox Signal"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Testa, R., Bonfigli, A.R., Prattichizzo, F., La Sala, L., De Nigris, V., and Ceriello, A. (2017). The \u201cMetabolic Memory\u201d Theory and the Early Treatment of Hyperglycemia in Prevention of Diabetic Complications. Nutrients, 9.","DOI":"10.3390\/nu9050437"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mvr.2014.06.010","article-title":"Role of Advanced Glycation End Product (AGE)-Induced Receptor (RAGE) Expression in Diabetic Vascular Complications","volume":"95","author":"Chawla","year":"2014","journal-title":"Microvasc. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/postgradmedj-2016-134579","article-title":"Skin Autofluorescence, a Non-Invasive Marker of Advanced Glycation End Products: Clinical Relevance and Limitations","volume":"93","author":"Webb","year":"2017","journal-title":"Postgrad. Med. J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.5551\/jat.30155","article-title":"Association of Advanced Glycation End Products with Coronary Artery Calcification in Japanese Subjects with Type 2 Diabetes as Assessed by Skin Autofluorescence","volume":"23","author":"Hangai","year":"2016","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Jiang, T., Liu, C., Hu, H., Dai, F., Xia, L., and Zhang, Q. (2022). Effectiveness of Early Advanced Glycation End Product Accumulation Testing in the Diagnosis of Diabetes: A Health Risk Factor Analysis Using the Body Mass Index as a Moderator. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.766778"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0009-8981(98)00128-4","article-title":"Comparison of Advanced Glycation Endproducts on Haemoglobin (Hb-AGE) and Haemoglobin A(1c) for the Assessment of Diabetic Control","volume":"277","author":"Turk","year":"1998","journal-title":"Clinica Chimica Acta"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/1476-511X-10-228","article-title":"Advanced Glycation End Products (AGEs) in Relation to Atherosclerotic Lipid Profiles in Middle-Aged and Elderly Diabetic Patients","volume":"10","author":"Chang","year":"2011","journal-title":"Lipids Health Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13098-022-00895-w","article-title":"The Association between Advanced Glycation End Products (AGEs) and ABC (Hemoglobin A1C, Blood Pressure, and Low-Density Lipoprotein Cholesterol) Control Parameters among Patients with Type 2 Diabetes Mellitus","volume":"14","author":"Rezaei","year":"2022","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/MNH.0000000000000062","article-title":"Advanced glycation end product accumulation: A new enemy to target in chronic kidney disease?","volume":"23","author":"Mallipattu","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.mvr.2015.01.002","article-title":"Skin autofluorescence is associated with carotid intima-media thickness, diabetic microangiopathy, and long-lasting metabolic control in type 1 diabetic patients. Results from Poznan Prospective Study","volume":"98","author":"Araszkiewicz","year":"2015","journal-title":"Microvasc Res."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Radi\u0107, J., Vu\u010dkovi\u0107, M., \u0110oga\u0161, H., Grubi\u0107, M., Belan\u010di\u0107, A., Tandara, L., \u0160oli\u0107 \u0160egvi\u0107, L., Novak, I., and Radi\u0107, M. (2024). Beyond Blood Sugar: Low Awareness of Kidney Disease among Type 2 Diabetes Mellitus Patients in Dalmatia\u2014Insights from the First Open Public Call. Medicina, 60.","DOI":"10.3390\/medicina60101643"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Radi\u0107, J., Belan\u010di\u0107, A., \u0110oga\u0161, H., Vu\u010dkovi\u0107, M., \u0110oga\u0161, T., Tandara, L., Grubi\u0107, M., \u0160oli\u0107 \u0160egvi\u0107, L., Novak, I., and Radi\u0107, M. (2025). The Power of Movement: Linking Physical Activity with Nutritional Health and Blood Sugar Balance in a Dalmatian Type 2 Diabetic Population. Nutrients, 17.","DOI":"10.3390\/nu17010187"},{"key":"ref_42","unstructured":"(2022, June 06). MedCalc MedCalc Statistical Software. Available online: https:\/\/www.medcalc.org\/en\/."},{"key":"ref_43","unstructured":"IBM Corp (2019). IBM SPSS Statistics for Windows, Version 26.0. 2019, IBM Corp."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: Global, Regional and Country-Level Diabetes Prevalence Estimates for 2021 and Projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, Regional, and National Burden of Diabetes from 1990 to 2021, with Projections of Prevalence to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4330\/wjc.v4.i4.90","article-title":"Role of Advanced Glycation End Products in Cardiovascular Disease","volume":"4","author":"Hegab","year":"2012","journal-title":"World J. Cardiol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Wang, Y., Liang, S., Zhou, Y., Tang, X., Ye, N., Huang, W., Tang, X., Jiang, B., and Pan, Y. (2025). The Associations between Skin Advanced Glycation End-Products and Framingham Cardiovascular Risk in Different Age Groups. Front. Cardiovasc. Med., 12.","DOI":"10.3389\/fcvm.2025.1491643"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arteri.2018.07.001","article-title":"Blood Pressure Control and Impact on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Critical Analysis of the Literature","volume":"31","year":"2019","journal-title":"Cl\u00ednica Investig. Arterioscler."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e9008","DOI":"10.1161\/JAHA.123.030772","article-title":"Real-World Systolic and Diastolic Blood Pressure Levels and Cardiovascular Mortality in Patients With Type 2 Diabetes\u2014Results From a Large Registry Cohort in Asia","volume":"12","author":"Seng","year":"2023","journal-title":"J. Am. Heart Assoc."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Dozio, E., Caldiroli, L., Molinari, P., Castellano, G., Delfrate, N.W., Romanelli, M.M.C., and Vettoretti, S. (2023). Accelerated AGEing: The Impact of Advanced Glycation End Products on the Prognosis of Chronic Kidney Disease. Antioxidants, 12.","DOI":"10.3390\/antiox12030584"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.numecd.2019.09.008","article-title":"Worldwide Burden of LDL Cholesterol: Implications in Cardiovascular Disease","volume":"30","author":"Mattiuzzi","year":"2020","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"118540","DOI":"10.1016\/j.atherosclerosis.2024.118540","article-title":"Course of the Effects of LDL-Cholesterol Reduction on Cardiovascular Risk over Time: A Meta-Analysis of 60 Randomized Controlled Trials","volume":"396","author":"Burger","year":"2024","journal-title":"Atherosclerosis"},{"key":"ref_53","first-page":"77","article-title":"Effects of SGLT2 Inhibitors and DPP-4 Inhibitors on Advanced Glycation End Products","volume":"74","author":"Kusunoki","year":"2023","journal-title":"Drug Res."},{"key":"ref_54","first-page":"e984","article-title":"Obesity and Cardiovascular Disease A Scientific Statement From the American Heart Association","volume":"143","author":"Poirier","year":"2021","journal-title":"Circulation"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ije\/dyr198","article-title":"The Influence of Hip Circumference on the Relationship between Abdominal Obesity and Mortality","volume":"41","author":"Cameron","year":"2012","journal-title":"Int. J. Epidemiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1001\/jamacardio.2018.0022","article-title":"Association of Body Mass Index with Lifetime Risk of Cardiovascular Disease and Compression of Morbidity","volume":"3","author":"Khan","year":"2018","journal-title":"JAMA Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"bqz006","DOI":"10.1210\/endocr\/bqz006","article-title":"Advanced Glycation End Products: Building on the Concept of the \u201cCommon Soil\u201d in Metabolic Disease","volume":"161","author":"Ruiz","year":"2020","journal-title":"Endocrinology"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Cesaro, A., De Michele, G., Fimiani, F., Acerbo, V., Scherillo, G., Signore, G., Rotolo, F.P., Scialla, F., Raucci, G., and Panico, D. (2023). Visceral Adipose Tissue and Residual Cardiovascular Risk: A Pathological Link and New Therapeutic Options. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1187735"},{"key":"ref_59","unstructured":"IDF (2025). IDF Global Clinical Practice Recommendations for Managing Type 2 Diabetes, IDF."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/eci.12627","article-title":"Lifestyle and Clinical Determinants of Skin Autofluorescence in a Population-Based Cohort Study","volume":"46","author":"Slagter","year":"2016","journal-title":"Eur. J. Clin. Invest."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/MNH.0000000000000835","article-title":"Skin Autofluorescence as Tool for Cardiovascular and Diabetes Risk Prediction","volume":"31","author":"Smit","year":"2022","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e012356","DOI":"10.1161\/JAHA.119.012356","article-title":"Glycemic Control, Preexisting Cardiovascular Disease, and Risk of Major Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: Systematic Review With Meta-Analysis of Cardiovascular Outcome Trials and Intensive Glucose Control Trials","volume":"8","author":"Giugliano","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"C89","DOI":"10.1152\/ajpcell.00470.2023","article-title":"Cardioprotective Antihyperglycemic Drugs Ameliorate Endoplasmic Reticulum Stress","volume":"326","author":"Mooradian","year":"2024","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Balogh, D.B., Wagner, L.J., and Fekete, A. (2023). An Overview of the Cardioprotective Effects of Novel Antidiabetic Classes: Focus on Inflammation, Oxidative Stress, and Fibrosis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097789"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.mehy.2006.11.054","article-title":"A Novel Pleiotropic Effect of Atorvastatin on Advanced Glycation End Product (AGE)-Related Disorders","volume":"69","author":"Yamagishi","year":"2007","journal-title":"Med. Hypotheses"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Zheng, W., Li, H., Go, Y., Chan, X.H., Huang, Q., and Wu, J. (2022). Research Advances on the Damage Mechanism of Skin Glycation and Related Inhibitors. Nutrients, 14.","DOI":"10.3390\/nu14214588"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00210-023-02459-9","article-title":"Evolving Insights into the Pleiotropic Cardioprotective Mechanisms of SGLT2 Inhibitors","volume":"396","author":"Fender","year":"2023","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1007\/s13300-019-00686-z","article-title":"The Pleiotropic Effects of Sodium\u2013Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit","volume":"10","author":"Patel","year":"2019","journal-title":"Diabetes Ther."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s13300-019-0657-8","article-title":"SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c\u2014Translating Evidence into Practice","volume":"10","author":"Ali","year":"2019","journal-title":"Diabetes Therapy"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective Studies\u2014Utility and Caveats","volume":"50","author":"Talari","year":"2020","journal-title":"J. R. Coll. Physicians Edinb."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee (2025). 6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes\u20142025. Diabetes Care, 48, S128\u2013S145.","DOI":"10.2337\/dc25-S006"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Mach, F., Koskinas, K.C., Roeters van Lennep, J.E., Tokg\u00f6zo\u011flu, L., Badimon, L., Baigent, C., Benn, M., Binder, C.J., Catapano, A.L., and De Backer, G.G. (2025). 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J.","DOI":"10.1016\/j.atherosclerosis.2025.120479"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae646","article-title":"2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension","volume":"45","author":"McCarthy","year":"2024","journal-title":"Eur. Heart J."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2418\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T16:25:46Z","timestamp":1759422346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/10\/2418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":73,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["biomedicines13102418"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13102418","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]}}}